Sepsis test match

In a bid to expand the label of its Xigris drotrecogin alfa treatment for severe sepsis, Eli Lilly and Co. has licensed from BioSite Inc. a point-of-care test that the pharma company hopes will not only make it possible to select patients most likely to benefit from treatment, but also help monitor the impact of therapy in real time.

BSTE (San Diego, Calif.) is developing a rapid point-of-care test that measures protein C as a marker for disease progression based on retrospective analysis of patients treated with Xigris...